A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
They include MET-233i, an injectable amylin analog that is Metsera’s answer to the sector’s search for a once-monthly dosing ...
MET-233i and Metsera’s other next-generation NuSH analog peptides are also engineered with Metsera’s HALO™ lipidation platform. Oral GLP-1 RA peptide program clinical trial initiated Metsera has ...
Metsera also has clinical trials underway for an injectable amylin analog called MET-233i and an oral GLP-1 peptide called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback